Outcomes and Treatment Sequences of Therapies with BCL2-and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

被引：2

作者：

Kutsch, Nadine ^{[1
,2
,3
]}

Ligtvoet, Rudy ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Linde, Hartmut

Illmer, Thomas

Doerfel, Steffen ^{[4
]}

Lipke, Joerg

Aldaoud, Ali

Schlag, Rudolf

Dengler, Jolanta

Al-Sawaf, Othman ^{[1
,2
,3
]}

Langerbeins, Petra ^{[1
,2
,3
]}

Cramer, Paula ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[5
]}

Hallek, Michael ^{[1
,2
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Fink, Anna Maria ^{[1
,2
,3
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Ctr Oncol Dresden, Freiberg, Meissen, Germany

[5] Univ Cologne, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185741

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Endpoint surrogacy in chronic lymphocytic leukemia: a pooled analysis of the German CLL Study Group
Simon, Florian
Ligtvoet, Rudy
Robrecht, Sandra
Cramer, Paula
Kutsch, Nadine
Fuerstenau, Moritz
Goede, Valentin
von Tresckow, Julia
Langerbeins, Petra
Fink, Anna
Huber, Henriette
Tausch, Eugen
Schneider, Christof
Wendtner, Clemens
Ritgen, Matthias
Dreyling, Martin
Mueller, Lothar
Jacobasch, Lutz
Heinz, Werner
Vehling-Kaiser, Ursula
Sivcheva, Lilly
Bottcher, Sebastian
Dreger, Peter
Illmer, Thomas
Gregor, Michael
Staber, Philipp
Stilgenbauer, Stephan
Niemann, Carsten
Kater, Arnon
Fischer, Kirsten
Eichhorst, Barbara
Hallek, Michael
Al-Sawaf, Othman
LEUKEMIA & LYMPHOMA, 2023, 64 : S1 - S2
[32] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
C-M Wendtner
M Ritgen
C D Schweighofer
G Fingerle-Rowson
H Campe
G Jäger
B Eichhorst
R Busch
H Diem
A Engert
S Stilgenbauer
H Döhner
M Kneba
B Emmerich
M Hallek
Leukemia, 2004, 18 : 1093 - 1101
[33] Characteristics, treatment, and outcomes of ≥80 year old patients with chronic lymphocytic leukemia (CLL) enrolled to prospective trials of the German CLL study group
Al-Sawaf, O.
Bahlo, J.
Fischer, K.
Herling, C.
M., Hochstaetter
Fink, A. M.
von Tresckow, J.
Langerbeins, P.
Cramer, P.
Stilgenbauer, S.
Wendtner, C. M.
Eichhorst, B.
Hallek, M.
Goede, V.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 139 - 139
[34] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
Wendtner, CM
Ritgen, M
Schweighofer, CD
Fingerle-Rowson, G
Campe, H
Jäger, G
Eichhorst, B
Busch, R
Diem, H
Engert, A
Stilgenbauer, S
Döhner, H
Kneba, M
Emmerich, B
Hallek, M
LEUKEMIA, 2004, 18 (06) : 1093 - 1101
[35] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
Cramer, Paula
Fuerstenau, Moritz
Robrecht, Sandra
Giza, Adam
Fink, Anna
Fischer, Kirsten
Langerbeins, Petra
Al-Sawaf, Othman
Tausch, Eugen
Schneider, Christof
Schetelig, Johannes
Dreger, Peter
Boettcher, Sebastian
Kreuzer, Karl-Anton
Schilhabel, Anke
Brueggemann, Monika
Kneba, Michael
Wendtner, Clemens
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
[36] Treatment response and health-related quality of life during management of chronic lymphocytic leukemia (CLL) - a metaanalysis of 3 phase III studies of the German CLL Study Group (GCLLSG)
Kutsch, N.
Goede, V
Robrecht, S.
Kelma, F.
Bahlo, J.
Fischer, K.
Fink, A. -M
Schlag, R.
Lange, E.
Weide, R.
Dreyling, M.
Jaeger, U.
Stilgenbauer, S.
Doehner, H.
Kneba, M.
Ritgen, M.
Wendtner, C. -M
Hallek, M.
Eichhorst, B.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 30 - 30
[37] Data quality improvement by a screening process within the CLL10 trial of the German CLL Study Group evaluating combined chemoimmunotherapy in firstline treatment of chronic lymphocytic leukemia
Cramer, P.
Westermann, A.
Frohs, S.
Fink, A. -M
Meister-Paetz, R.
Fischer, K.
Kreuzer, K. -A
Hallek, M.
Eichhorst, B.
Stilgenbauer, S.
Doehner, H.
Wendtner, C-M
ONKOLOGIE, 2011, 34 : 142 - 142
[38] Comparative Analysis of Patient Characteristics, BTK Treatment, and Treatment Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A CrossNational Study between the United States and China
Liu, Yin
Chen, Yanfei
Xiao, Yue
Huang, Ruijian
Jiang, Feng
Zhou, Jifang
BLOOD, 2023, 142
[39] Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)
Cramer, Paula
Langerbeins, Petra
Eichhorst, Barbara
Hallek, Michael
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (01) : 9 - 18
[40] Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)
De Silva, Nisha
Robrecht, Sandra
Zhang, Can
Cramer, Paula
Fink, Anna-Maria
Fischer, Kirsten
Goede, Valentin
Herling, Carmen D.
Hoechstetter, Manuela
Wendtner, Clemens-Martin
Hallek, Michael
Eichhorst, Barbara F.
BLOOD, 2019, 134

← 1 2 3 4 5 →